DNA X, Inc. received notification from the Nasdaq Hearings Panel that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders' equity of at least $2.5 million. Although compliance was restored as of July 24, 2026, securities remain subject to delisting if rules are violated until November 18, 2026. The company is now under mandatory panel monitoring until August 28, 2027; failure to maintain equity compliance during this period will trigger an automatic delisting determination without a cure period. DNA X, Inc. operates in the biotechnology industry and develops automated systems for high-throughput DNA sequencing.
